A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Epidermolysis Bullosa Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00311766
• Other study ID #: SSEB
• Secondary ID: 0003031
• Status: Terminated
• Phase: Phase 2
• First received: April 4, 2006
• Last updated: April 25, 2014
• Start date: February 2006
• Est. completion date: November 2012

Study information

• Verified date: April 2014
• Source: RegeneRx Biopharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate a treatment to enhance the healing of acute and chronic nonhealing cutaneous wounds, such as the erosions experienced by patients with Epidermolysis Bullosa (EB), by the known activity of thymosin beta 4 (Tβ4). Funding Source - FDA Office of Orphan Product Development (OOPD).

Description:

EB is a group of genetic diseases characterized by skin-blistering and lesion-formation after minor trauma to the skin. This family of disorders, most of which are inherited, range in severity from mild to the severely disabling and life-threatening. Tβ4 is a synthetically-produced copy of a naturally-occurring 43 amino acid peptide that has wound healing and anti-inflammatory properties and can up-regulate the expression of laminin-5.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 30
• Est. completion date: November 2012
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• Informed Consent form signed by the patient or patient's legal representative; also, if the patient is under the age of majority but capable of providing assent, signed assent from the patient

• Diagnosis of junctional or dystrophic EB.

• Patients who present with Hallopeau-Siemens subtype may be enrolled.

• At least one active, unroofed EB erosion on the limb or on the trunk.

• Lesion size 5 to 50 cm2, inclusive.

• Stable lesion present for 14-60 days before enrollment.

• More that one member in a family can be enrolled as long as that member is treated to a different cohort with an assurance that the study medication will not be shared.

• No clinically significant abnormalities (Grade 2 or higher on the National Cancer Institute [NCI] toxicity scale) on Screening laboratory tests, except for the following specific laboratory threshold result: albumin must be 2 g/dL or higher; hemoglobin must be 8 g/dL or higher.

Exclusion Criteria:

• Clinical evidence of local infection of the index (targeted) lesion.

• Use of any investigational drug within the 30 days before enrollment.

• Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.

• Use of systemic or topical steroidal therapy within the 30 days before enrollment.Inhaled steroids are allowed.

• Use of systemic antibiotics within the 7 days before enrollment.

• Current or former malignancy.

• Arterial or venous disorder resulting in ulcerated wounds.

• Diabetes mellitus.

• Pregnancy or breastfeeding during the study. (A serum pregnancy test will be performed at Screening for female patients of childbearing potential.)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Epidermolysis Bullosa

Intervention

Drug:
• Thymosin Beta 4
Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
• Placebo
Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
RegeneRx Biopharmaceuticals, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)		70 days	Yes
Secondary	Number of Participants Whose Wounds Have Healed	Wound healing means that the wound has closed without any drainage	56 days	No